Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Fakhra, MIVAC |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,[1] a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.[1][2][3] It is currently in phase III.[4][5] It received emergency use authorization in Iran on 9 September 2021.[4]
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1][7]
:3
was invoked but never defined (see the help page).© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search